Novartis AG Q1 2010 Financial Summary
Business Context and Reporting Period
This Form 6-K filing covers the first quarter of 2010 (ended March 31, 2010) for Novartis AG, a global healthcare company headquartered in Basel, Switzerland. The period reflects strong portfolio rejuvenation driven by recently launched products and significant sales recognition from A (H1N1) pandemic flu vaccine contracts. The company is implementing strategic priorities under new leadership focused on innovation, growth, and productivity, while preparing for the acquisition of a 77% majority stake in Alcon Inc., expected to close in the second half of 2010.
Key Financial Metrics
| Metric (USD) | Q1 2010 | Q1 2009 | % Change (Reported) | % Change (Constant Currency) |
|---|---|---|---|---|
| Net Sales | 12,131 million | 9,709 million | 25% | 18% |
| Operating Income | 3,511 million | 2,347 million | 50% | 42% |
| Net Income | 2,948 million | 1,975 million | 49% | 41% |
| Earnings Per Share (EPS) | 1.29 | 0.87 | 48% | 40% |
| Free Cash Flow (before dividends) | 2,903 million | 1,506 million | 93% | N/A |
| Core Operating Income | 3,865 million | 2,611 million | 48% | 41% |
| Core Operating Margin | 31.9% | 26.9% | +5.0 pts | N/A |
Liquidity and Debt: Total financial debt stood at USD 17.9 billion (USD 4.5 billion current, USD 13.4 billion non-current) as of March 31, 2010, following a USD 5 billion bond issuance in March. Net liquidity decreased to USD 2.0 billion from USD 3.5 billion at year-end 2009, primarily due to the USD 4.5 billion dividend payment. The debt-to-equity ratio rose to 0.32:1.
Material Changes vs. Prior Period
- Revenue Drivers: Net sales growth was driven by a USD 1.1 billion contribution from A (H1N1) pandemic vaccine sales and USD 1.9 billion from products launched since 2007 (representing 16% of total sales). Currency movements contributed 7 percentage points to reported growth.
- Divisional Performance:
- Vaccines and Diagnostics: Sales surged 451% (436% cc) to USD 1.4 billion, turning an operating loss of USD 67 million in Q1 2009 into a profit of USD 839 million.
- Pharmaceuticals: Sales grew 13% (7% cc) to USD 7.3 billion, with strong volume growth in Oncology (+14% cc) and Neuroscience/Ophthalmics (+24% cc).
- Sandoz: Sales increased 16% (9% cc) to USD 2.0 billion, aided by the integration of EBEWE Pharma and biosimilar launches.
- Profitability: Operating income margin improved 4.7 percentage points to 28.9%. Core operating margin improved 5.0 percentage points to 31.9%, supported by productivity initiatives and favorable volume mix.
- Impairments: A pre-tax impairment charge of USD 152 million was recorded for the discontinuation of the PTZ601 development project.
Guidance, Outlook, and Risks
Outlook: Novartis reaffirms expectations for Group net sales to grow at a mid-single-digit rate in constant currencies in 2010 (excluding Alcon) and anticipates an improvement in the operating income margin. The company expects reported and constant currency growth rates to be broadly similar if exchange rates remain stable.
Strategic Initiatives:
- Alcon Acquisition: On track to complete the acquisition of a 77% stake in Alcon in H2 2010, followed by a merger proposal for the remaining 23% stake.
- US Restructuring: Announced a streamlining of the US Pharmaceuticals business, reducing approximately 383 full-time equivalent positions with a planned one-time charge of USD 24 million in Q2 2010.
- Innovation Pipeline: Received priority review status for Tasigna (cancer) and Gilenia (multiple sclerosis) in the US. Achieved approvals for Menveo (meningitis vaccine) in the US and EU.
Risks and Contingencies:
- Legal Proceedings: Ongoing investigations by the US Attorney's Office regarding off-label marketing of Trileptal (plea agreement pending) and five other products. Provisions for Trileptal investigations totaled USD 397 million as of March 31, 2010.
- Litigation: Significant exposure in Zometa/Aredia (osteonecrosis of the jaw) and Zelnorm (cardiovascular injuries) litigation, with trials scheduled for 2010.
- Regulatory: Uncertainty regarding the approval of new products and potential pricing pressures in key markets.
Investor Verification Checklist
- Verify the sustainability of the A (H1N1) vaccine revenue contribution, as the company noted it has largely finished deliveries for government contracts.
- Monitor the timeline and regulatory approval status for the Alcon acquisition and subsequent merger.
- Track the progress of the US Pharmaceuticals restructuring and the realization of anticipated annual cost savings of USD 56 million starting in 2011.
- Review updates on the Trileptal criminal/civil investigations and the outcome of pending Zometa and Zelnorm trials.
- Assess the impact of the USD 152 million impairment charge on future R&D spending and pipeline development.